CTx-2106

About Cingulate

Cingulate is a neuroscience-focused biotech developing treatments for CNS disorders via its proprietary Precision Timed Release™ (PTR™) drug delivery platform. Its strategy is to create single-tablet, multi-release formulations that offer rapid onset and controlled duration of action, primarily targeting unmet needs in ADHD and anxiety. The company's most advanced candidates, CTx-1301 and CTx-1302, are in late-stage development for ADHD, representing its nearest-term value inflection points. As a pre-revenue, publicly traded entity, Cingulate's progress is measured by clinical milestones and its ability to navigate a competitive therapeutic landscape.

Therapeutic Areas

Other Anxiety Disorder Drugs